Population pharmacokinetics of oxaliplatin after intraperitoneal administration with hyperthermia in Wistar rats
- 1 July 2018
- journal article
- research article
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 119, 22-30
Abstract
No abstract availableKeywords
Funding Information
- Fundación Navarro Tripodi
- Proyecto Bancaja-UMH
This publication has 51 references indexed in Scilit:
- A mechanism-Based Approach for Absorption Modeling: The Gastro-Intestinal Transit Time (GITT) ModelThe AAPS Journal, 2012
- An Integrated Disease/Pharmacokinetic/Pharmacodynamic Model Suggests Improved Interleukin-21 Regimens Validated Prospectively for Mouse Solid CancersPLOS Computational Biology, 2011
- Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects ModelsThe AAPS Journal, 2011
- Pharmacokinetic and Pharmacodynamic Analysis of Hyperthermic Intraperitoneal Oxaliplatin-Induced Neutropenia in Subjects with Peritoneal CarcinomatosisThe AAPS Journal, 2011
- Importance of Shrinkage in Empirical Bayes Estimates for Diagnostics: Problems and SolutionsThe AAPS Journal, 2009
- Long-term platinum retention after treatment with cisplatin and oxaliplatinBMC Clinical Pharmacology, 2008
- Population pharmacokinetic modelling of the enterohepatic recirculation of diclofenac and rofecoxib in ratsBritish Journal of Pharmacology, 2008
- Pharmacokinetics of heated intraperitoneal oxaliplatinCancer Chemotherapy and Pharmacology, 2007
- Heated intra-operative intraperitoneal oxaliplatin alone and in combination with intraperitoneal irinotecan: Pharmacologic studiesEuropean Journal of Surgical Oncology, 2006
- Hyperthermia enhances the cytotoxicity and platinum-DNA adduct formation of lobaplatin and oxaliplatin in cultured SW 1573 cellsJournal of Cancer Research and Clinical Oncology, 1997